A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)
CompletedNCT03724916
Millennium Pharmaceuticals, Inc.Lupus Erythematosus, Systemic, Systemic Lupus Erythematosus
Start: 2018-11-26End: 2021-11-04Updated: 2024-03-29